# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $22 to ...
Oppenheimer analyst Francois Brisebois reiterates Kala Bio (NASDAQ:KALA) with a Outperform and maintains $15 price target.
HC Wainwright & Co. analyst Yi Chen maintains Kala Bio (NASDAQ:KALA) with a Buy and lowers the price target from $24 to ...
Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(3.41) per share which missed the analyst consensus estimate o...
HC Wainwright & Co. analyst Yi Chen reiterates Kala Bio (NASDAQ:KALA) with a Buy and maintains $24 price target.
Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(4.36) per share. This is a 76.96 percent increase over losses...
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and...